Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 8Sarcoma 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liver Neoplasms 2Central Nervous System Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Testicular Germ Cell Tumor 1Seminoma 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Prostatic Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Germ Cell Cancer 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Glandular and Epithelial 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

pembrolizumab 26Magnetic Resonance Spectroscopy 14Nivolumab 13Docetaxel 13Specimen Handling 11Radiotherapy 9Paclitaxel 9Radiosurgery 8Early Intervention, Educational 8Cyclophosphamide 8Gemcitabine 7atezolizumab 6Taxes 6Surveys and Questionnaires 6Standard of Care 6Psychiatric Rehabilitation 6Ipilimumab 6Carboplatin 6sargramostim 5Pemetrexed 5Methods 5motexafin gadolinium 4fludarabine 4X-Rays 4Interviews as Topic 4Immunoglobulin G 4Fluorouracil 4Educational Status 4Cisplatin 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × ixabepilone × Genitourinary × Clear all
NCT01012362 2017-12-28

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
31 enrolled 12 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡